LL-37: Human Cathelicidin Antimicrobial Peptide Research

Background

LL-37 is a 37-amino acid peptide that represents the sole cathelicidin-derived antimicrobial peptide identified in humans. The peptide is generated by proteolytic cleavage of its precursor protein, human cationic antimicrobial protein 18 (hCAP18), by the serine protease proteinase 3. The name "LL-37" derives from its 37-residue length and N-terminal leucine-leucine dipeptide.

LL-37 is expressed by multiple cell types including neutrophils, monocytes, macrophages, natural killer cells, and epithelial cells of the skin, respiratory tract, gastrointestinal tract, and urogenital system. Zanetti (2004), publishing in Journal of Leukocyte Biology, provided a comprehensive review of cathelicidin biology documenting the peptide's expression patterns and processing mechanisms across these tissues.

Antimicrobial Activity

The antimicrobial properties of LL-37 have been documented extensively in the peer-reviewed literature. Durr et al. (2006), publishing in Biochimica et Biophysica Acta, characterized LL-37 as the only human member of the cathelicidin family of antimicrobial peptides and reviewed its broad-spectrum activity against both Gram-positive and Gram-negative bacteria, as well as certain fungi and enveloped viruses.

The peptide's antimicrobial mechanism involves direct interaction with microbial membranes. In solution, LL-37 adopts an amphipathic alpha-helical structure that enables it to insert into lipid bilayers. Xhindoli et al. (2016), publishing in Biochimica et Biophysica Acta, documented that the peptide's cationic charge facilitates initial electrostatic interaction with the negatively charged bacterial membrane surface, followed by hydrophobic insertion that disrupts membrane integrity.

In vitro minimum inhibitory concentration (MIC) assays have established the peptide's activity against clinically relevant organisms. Published MIC values vary by organism and assay conditions, as LL-37 activity is sensitive to salt concentration, pH, and the presence of serum proteins.

Immunomodulatory Functions

Beyond direct antimicrobial activity, LL-37 has documented immunomodulatory properties. The peptide functions as a chemoattractant for neutrophils, monocytes, and T cells, as reported by Yang et al. (2000) in the Journal of Experimental Medicine. The chemotactic activity was demonstrated using Boyden chamber migration assays and was shown to be mediated through the formyl peptide receptor-like 1 (FPRL1) receptor.

Published research has also documented LL-37's interactions with bacterial endotoxin (lipopolysaccharide, LPS). The peptide binds LPS and can modulate LPS-induced inflammatory responses in cell culture systems. This LPS-neutralizing activity has been characterized using Limulus amebocyte lysate assays and cytokine ELISA measurements in macrophage cell cultures.

Structural Studies

The three-dimensional structure of LL-37 has been characterized using multiple biophysical techniques. Sancho-Vaello et al. (2020), publishing in Scientific Reports, reported the crystal structure of LL-37 in the presence of membrane mimics, revealing that the peptide forms oligomeric assemblies consistent with a channel-forming mechanism of membrane disruption. The structural data was obtained through X-ray crystallography and was corroborated by circular dichroism spectroscopy and molecular dynamics simulations.

Laboratory Handling Notes

LL-37 is supplied as a lyophilized powder and should be stored at -20°C. The peptide is soluble in water and dilute acid solutions. Researchers should note that LL-37 is susceptible to degradation by serine proteases and should consider this when designing experimental protocols involving biological matrices.

All findings discussed in this article are derived from peer-reviewed investigations. This compound is intended for research applications only.

References

1. Durr, U.H.N., Sudheendra, U.S., Ramamoorthy, A. "LL-37, the only human member of the cathelicidin family of antimicrobial peptides." Biochimica et Biophysica Acta 1758.9 (2006): 1408-1425.
2. Yang, D., et al. "LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells." Journal of Experimental Medicine 192.7 (2000): 1069-1074.
3. Sancho-Vaello, E., et al. "The structure of the antimicrobial human cathelicidin LL-37 shows oligomerization and channel formation in the presence of membrane mimics." Scientific Reports 10 (2020): 17356.
4. Zanetti, M. "Cathelicidins, multifunctional peptides of the innate immunity." Journal of Leukocyte Biology 75.1 (2004): 39-48.